World

Personalized cancer vaccine cuts risk of melanoma returning, trial finds

A clinical study found the vaccine, given with immunotherapy, reduced the risk of death or the disease coming back by 42 percent.

By the Meridian desk

· 3 hr ago

Personalized cancer vaccine cuts risk of melanoma returning, trial finds
Photograph: BBC Arabic

What to know

  • The trial tested a vaccine tailored to the individual patient.
  • It was administered alongside immunotherapy treatment.
  • The combined approach lowered the risk of death or melanoma recurrence by 42 percent.

A personalized cancer vaccine, used together with immunotherapy, reduced the risk of death or the return of melanoma by 42 percent in a clinical trial, according to the BBC. The finding points to a treatment approach built around each patient rather than a single standard formula.

The report gives no details on how many patients took part, how long they were followed, or where the trial was conducted. It also does not say whether the results have been peer-reviewed or published, so independent confirmation of the 42 percent figure is not yet available.

Reporting credit

Written by the Meridian desk. The underlying reporting is by BBC Arabic.

Cancer Vaccines Melanoma Clinical Trials

Read next